BAUSCH HEALTH COS INC (BHC) Stock Fundamental Analysis
NYSE:BHC • CA0717341071
6.07 USD
+0.09 (+1.51%)
Last: Feb 24, 2026, 02:56 PM
Taking everything into account, BHC scores 4 out of 10 in our fundamental rating. BHC was compared to 192 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of BHC while its profitability can be described as average. BHC is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
- BHC had positive earnings in the past year.
- BHC had a positive operating cash flow in the past year.
- In the past 5 years BHC reported 4 times negative net income.
- Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 0.60%, BHC is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
- The Return On Invested Capital of BHC (7.78%) is better than 86.46% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BHC is significantly below the industry average of 12.96%.
- The last Return On Invested Capital (7.78%) for BHC is above the 3 year average (6.89%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- BHC has a Profit Margin of 1.53%. This is in the better half of the industry: BHC outperforms 79.17% of its industry peers.
- Looking at the Operating Margin, with a value of 21.28%, BHC belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
- BHC's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 70.65%, BHC is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
- BHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BHC is still creating some value.
- Compared to 1 year ago, BHC has more shares outstanding
- Compared to 5 years ago, BHC has more shares outstanding
- BHC has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 0.29, we must say that BHC is in the distress zone and has some risk of bankruptcy.
- BHC has a Altman-Z score (0.29) which is in line with its industry peers.
- The Debt to FCF ratio of BHC is 21.00, which is on the high side as it means it would take BHC, 21.00 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 21.00, BHC is in the better half of the industry, outperforming 76.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.29 |
ROIC/WACC1.18
WACC6.58%
2.3 Liquidity
- BHC has a Current Ratio of 1.47. This is a normal value and indicates that BHC is financially healthy and should not expect problems in meeting its short term obligations.
- BHC has a Current ratio of 1.47. This is in the lower half of the industry: BHC underperforms 71.35% of its industry peers.
- A Quick Ratio of 1.08 indicates that BHC should not have too much problems paying its short term obligations.
- The Quick ratio of BHC (1.08) is worse than 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
- The earnings per share for BHC have decreased by 0.00% in the last year.
- The Earnings Per Share has been decreasing by -1.13% on average over the past years.
- BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.66%.
- The Revenue has been growing slightly by 5.04% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- The Earnings Per Share is expected to decrease by -2.02% on average over the next years.
- The Revenue is expected to decrease by -1.38% on average over the next years.
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 1.61, which indicates a rather cheap valuation of BHC.
- Based on the Price/Earnings ratio, BHC is valued cheaper than 99.48% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.64, BHC is valued rather cheaply.
- Based on the Price/Forward Earnings ratio of 1.42, the valuation of BHC can be described as very cheap.
- BHC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BHC is cheaper than 98.96% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 27.75. BHC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.61 | ||
| Fwd PE | 1.42 |
4.2 Price Multiples
- 94.79% of the companies in the same industry are more expensive than BHC, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, BHC is valued cheaper than 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.27 | ||
| EV/EBITDA | 6.41 |
4.3 Compensation for Growth
- BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BHC has a very decent profitability rating, which may justify a higher PE ratio.
- A cheap valuation may be justified as BHC's earnings are expected to decrease with -7.27% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
5. Dividend
5.1 Amount
- No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:BHC (2/24/2026, 2:56:06 PM)
6.07
+0.09 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-28 2026-04-28
Inst Owners45.78%
Inst Owner Change-1.83%
Ins Owners10.79%
Ins Owner Change11.68%
Market Cap2.25B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.45 (22.73%)
Short Float %1.66%
Short Ratio2.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)1.27%
PT rev (3m)2.53%
EPS NQ rev (1m)-0.78%
EPS NQ rev (3m)-1.37%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.54%
Revenue NQ rev (1m)-0.48%
Revenue NQ rev (3m)-0.48%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.61 | ||
| Fwd PE | 1.42 | ||
| P/S | 0.22 | ||
| P/FCF | 2.27 | ||
| P/OCF | 1.61 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.41 |
EPS(TTM)3.77
EY62.11%
EPS(NY)4.29
Fwd EY70.66%
FCF(TTM)2.68
FCFY44.11%
OCF(TTM)3.78
OCFY62.19%
SpS27.68
BVpS-1.49
TBVpS-44.41
PEG (NY)0.12
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.29 |
F-Score6
WACC6.58%
ROIC/WACC1.18
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.07%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
Can you provide the valuation status for BAUSCH HEALTH COS INC?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.